Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Fox Chase Cancer Center, Philadelphia, PA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Philadelphia, PA
Treatments:ChemotherapyHospital:Fox Chase Cancer Center
Drugs:Journal:Link
Date:Aug 2005

Description:

Patients: This Phase II study involved 30 patients, of which 27 were evaluated. The median age was 61. 23 patients had ovarian cancer and 4 had primary peritoneal cancer.

Treatment: The treatment consisted of one chemotherapeutic drug: gefitinib.

Toxicity: Grade 3-4 toxicities were neutropenia, gastrointestinal (diarrhea, nausea, emesis) and dermatological.

Results: The overall survival was 12.2 months. The authors concluded: "Gefitinib was well tolerated but had minimal activity in unscreened patients with recurrent ovarian or primary peritoneal carcinoma."

Correspondence: Dr. Russell J. Schilder, MD





Back